Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization.
Metabolon Inc. is backed by a group of top-tier investors including Sevin Rosen Funds, Harris & Harris and Aurora Funds.
For more information on Metabolon, Inc. visit their website at www.metabolon.com.